American Association for Cancer Research
15357163mct110474-sup-f5_pdf_532k.pdf (532.38 kB)

Supplementary Figure 5 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Download (532.38 kB)
journal contribution
posted on 2023-04-03, 13:49 authored by Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Matthew Burger, Mark Knapp, Dario Sterker, Christian Schnell, Daniel Guthy, Tobi Nagel, Marion Wiesmann, Saskia Brachmann, Christine Fritsch, Marion Dorsch, Patrick Chène, Kevin Shoemaker, Alain De Pover, Daniel Menezes, Georg Martiny-Baron, Doriano Fabbro, Christopher J. Wilson, Robert Schlegel, Francesco Hofmann, Carlos García-Echeverría, William R. Sellers, Charles F. Voliva

PDF file - 532K



Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clinical compound, we sought to identify additional phosphoinositide 3-kinase (PI3K) inhibitors from different chemical classes with a different selectivity profile. The key to achieve these objectives was to couple a structure-based design approach with intensive pharmacologic evaluation of selected compounds during the medicinal chemistry optimization process. Here, we report on the biologic characterization of the 2-morpholino pyrimidine derivative pan-PI3K inhibitor NVP-BKM120. This compound inhibits all four class I PI3K isoforms in biochemical assays with at least 50-fold selectivity against other protein kinases. The compound is also active against the most common somatic PI3Kα mutations but does not significantly inhibit the related class III (Vps34) and class IV (mTOR, DNA-PK) PI3K kinases. Consistent with its mechanism of action, NVP-BKM120 decreases the cellular levels of p-Akt in mechanistic models and relevant tumor cell lines, as well as downstream effectors in a concentration-dependent and pathway-specific manner. Tested in a panel of 353 cell lines, NVP-BKM120 exhibited preferential inhibition of tumor cells bearing PIK3CA mutations, in contrast to either KRAS or PTEN mutant models. NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models. NVP-BKM120 behaves synergistically when combined with either targeted agents such as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide. The pharmacological, biologic, and preclinical safety profile of NVP-BKM120 supports its clinical development and the compound is undergoing phase II clinical trials in patients with cancer. Mol Cancer Ther; 11(2); 317–28. ©2011 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager